Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Trial Type:  Treatment
Treatment/Intervention:  histone deacetylase inhibitor therapy, histone deacetylase targeted therapy
Results 1-25 of 74 for your search:
Start Over
Exemestane with or without Entinostat in Treating Patients with Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: E2112, NCI-2014-00746, ECOG-E2112, NCT02115282
Vorinostat and Etoposide in Treating Younger Patients With Refractory or Relapsed Solid Tumors
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 4 to 21
Trial IDs: 10-096, NCI-2011-00493, NCT01294670
Lenalidomide and Romidepsin with or without Dexamethasone in Treating Patients with Recurrent or Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma, or Multiple Myeloma
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: 18 to 80
Trial IDs: 1112009392, NCI-2015-00921, RM-PTCL-PI-0021, NCT01742793
Romidepsin and Lenalidomide in Treating Patients with Relapsed or Refractory Lymphoma or Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 12-170, NCI-2013-00005, NCT01755975
Vorinostat, Gemcitabine Hydrochloride, and Docetaxel in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 12-104, NCI-2013-01735, UPCI 12-104, NCT01879085
Romidepsin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients with Metastatic Inflammatory Breast Cancer
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: 13C.387, NCI-2013-01695, 080-38270-J94401, 2013-35, NCT01938833
Pralatrexate and Romidepsin in Treating Patients with Relapsed or Refractory Lymphoma or Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAJ5656, NCI-2014-01986, NCT01947140
Azacitidine and Romidepsin in Treating Patients With Relapsed or Refractory Lymphoid Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Over 18
Trial IDs: AAAM3752, NCI-2014-00121, NCT01998035
Ixazomib, Panobinostat, and Dexamethasone in Treating Patients with Relapsed or Refractory Multiple Myeloma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: CASE 4A13, NCI-2014-00228, CLBH589DUS92T, NCI-2014-00267, US92T, NCT02057640
Ricolinostat in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: AAAM4054, NCI-2014-01521, NCT02091063
Carfilzomib, Romidepsin, and Lenalidomide in Treating Patients with Relapsed or Refractory B-cell and T-cell Lymphomas
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-179, NCI-2015-00109, NCT02341014
Cisplatin and Romidepsin in Treating Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: IIT-2014-PS-BRST-CISRomiTNBC, NCI-2015-01524, RM-CL-BRST-PI-002783, STUDY00002219, NCT02393794
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Patients with Refractory or Relapsed Mixed Lineage Leukemia Rearranged Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 21 and under
Trial IDs: RELMLL, NCI-2015-00602, MLL REC, NCT02419755
Mocetinostat and Brentuximab Vedotin in Treating Patients with Relapsed or Refractory Hodgkin Lymphoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-232, NCI-2015-00780, NCT02429375
Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in NSCLC With Expansion Cohorts in NSCLC and Melanoma
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: SNDX-275-0601, NCI-2015-01180, NCT02437136
Romidepsin in Conditioning and Maintenance in Patients with T-cell Leukemia or Lymphoma Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 to 70
Trial IDs: 2015-0047, NCI-2015-01555, NCT02512497
Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510
Bortezomib, Vorinostat, and Combination Chemotherapy in Treating Infants with Newly Diagnosed Acute Lymphoblastic Leukemia
Status: Temporarily closed
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 and under
Trial IDs: TINI, NCI-2015-01493, NCT02553460
Lenalidomide and High-Dose Chemotherapy before Stem Cell Transplant in Treating Patients with Relapsed or Refractory, Diffuse Large B-Cell Lymphoma of the ABC Subtype
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 15 to 65
Trial IDs: 2015-0558, NCI-2015-01938, NCT02589145
Pembrolizumab and Vorinostat in Treating Patients with Stage IV Non-small Cell Lung Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MCC-18494, NCI-2016-00309, NCT02638090
Randomized Phase 2 Study of Atezolizumab and Entinostat in Patients With aTN Breast Cancer With Phase 1b Lead In
Status: Not yet active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: SNDX-275-0602, NCI-2016-01257, NCT02708680
Vorinostat in Treating Patients with Metastatic Melanoma of the Eye
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: AAAO5917, NCI-2012-00860, CUMC-IRBAAAO5917, MSKCC-12-027, 9111, 12-027, NCT01587352
Sorafenib Tosylate, Valproic Acid, and Sildenafil Citrate in Treating Patients with Recurrent or Progressive High-Grade Glioma
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: MCC-14816, NCI-2013-00705, CTC-11-011, MCC-14816 (CTC-11-011), NCT01817751
Chemotherapy, Stem Cell Transplant, and Romidepsin in Treating Patients with T-cell Non-Hodgkin Lymphoma
Status: Active
Phase: Phase II
Type: Treatment
Age: Over 16
Trial IDs: 13-020, NCI-2013-01365, NCT01908777
Azacitidine and Entinostat Followed by Nivolumab or Nivolumab Alone in Treating Patients with Recurrent Metastatic Non-small Cell Lung Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Over 18
Trial IDs: J1353, NCI-2013-02334, J1353/ NA_00084192, NA_00084192, NA_00084192/CIR00003289, NCT01928576
Start Over